Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afimkibart in Moderate to Severe Rheumatoid Arthritis
NCT07137598Phase 2Recruiting
- Sponsor
- Roche
- Start
- Dec 2025
- Primary completion
- Apr 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of afimkibart in rheumatoid arthritis (RA), sponsored by Roche. Started Dec 2025; status: recruiting.
02
Drugs
afimkibart
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07137598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07137598.